
Opioid-Induced Hyperalgesia (OIH) Model
In opioid-induced hyperalgesia, prolonged opioid use paradoxically increases sensitivity to pain: rather than needing more opioid for the same effect, the patient experiences more pain at the same or higher doses. Where tolerance is driven mainly by opioid receptor desensitization and downregulation, hyperalgesia reflects enhanced pain signaling pathways.
In Transpharmation’s model, mice receive morphine (10 mg/kg) twice daily from day 0 to day 4. Mechanical allodynia (von Frey) and thermal sensitivity (hot plate) are measured before dosing, on day 5 to confirm hyperalgesia and randomize treatment groups, and 1 hour after compound dosing on days 6 and 7. The hyperalgesia appears as early as day 3 and is sustained to at least day 14, giving a robust and repeatable window in both endpoints.
Methadone and buprenorphine serve as positive controls. The model lets clients test whether their compounds reverse established OIH caused by long-term opioid use.
BID dosing of Morphine (10mg/kg) D0-D4
Primary species: Mouse
Primary endpoint: Mechanical allodynia (von Frey) and Thermal allodynia (hot plate)
Positive control: Methadone, Buprenorphine
Recommended N of 10


NP: Day 5
Two-way repeated measure ANOVA with Dunnett's multiple comparisons post-hoc test